← 返回

更正:HLA-A2.1 限制性 ECM1 衍生表位 LA 通过 DC 交叉激活启动 CD8+ T 和 NK 细胞:一种新型治疗性肿瘤疫苗

英文原题:Correction to: HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine.

查看英文原题

Correction to: HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine.

PubMed 2021/09/29(内容时间) J Hematol Oncol Q1 · IF 47.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

摘要

这条来源本身就没有摘要(PubMed 未提供),不是「还没翻译」。可以点最下面的「在 PubMed 查看」打开原文献页面。

论文信息

作者
Yu Z、Liu W、He Y、Sun M、Yu J、Jiao X、Han Q、Tang H
第一作者单位
Department of Pharmacology, School of Pharmacy, China Medical University, No. 13, Beihai Road, Dadong District, Shenyang, Liaoning Province, China.China
通讯作者单位
Department of Pharmacology, School of Pharmacy, China Medical University, No. 13, Beihai Road, Dadong District, Shenyang, Liaoning Province, China. mjwei@cmu.edu.cn.China
文献类型
勘误
期刊
Journal of hematology & oncology2021 Sep 29
原文标识
PubMed 34587994 · DOI 10.1186/s13045-021-01176-1